Status:
COMPLETED
ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Collaborating Sponsors:
Peking University People's Hospital
First Affiliated Hospital of Guangxi Medical University
Conditions:
Hematopoietic Stem Cell Transplantation
Antithymocyte Globulin
Eligibility:
All Genders
14-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare the incidences of GVHD and viral infections in haploidentical hematopoietic stem cell transplant recipients receiving different dose of antithymocyte globulin (...
Detailed Description
Allogeneic hematopoietic stem cell transplantation (allo-HSCT)is the only therapeutic option for many hematological malignancies. Unfortunately, about 75% of patients who require allo-HSCT lack human ...
Eligibility Criteria
Inclusion
- A patient age of 14-65 years
- Haploidentical hematopoietic stem cell transplant recipient
- Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
Exclusion
- Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)
- Patients with any conditions not suitable for the trial (investigators' decision)
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2018
Estimated Enrollment :
412 Patients enrolled
Trial Details
Trial ID
NCT01883180
Start Date
June 1 2013
End Date
January 1 2018
Last Update
April 24 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515